Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study is a research paper published in Journal of Clinical Oncology (2007). On theSindex it has a DataRank of 13.3. It has been cited 427 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.909
From this paper's citation signal
Citation Network Contribution
12.4
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
NCI NIH HHS
Grant: N01-CM17101
NCI NIH HHS
Grant: N01-CM-07003-CM74S
NCI NIH HHS
Grant: N01-CM17105
NCI NIH HHS
Grant: N01-CM-17003
NCI NIH HHS
Grant: N01-CM-17102
FWCI
28.02
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals